Maravai LifeSciences (NASDAQ: MRVI) reported Q1 EPS of $0.01, $0.06 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $65.8 million versus the consensus estimate of $52.9 million.

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $205-215 million, versus the consensus of $204.9 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.